-

Trinseo PLC (TSE) Class Action Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Trinseo PLC

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Trinseo PLC (NYSE: TSE) between May 3, 2021 and March 27, 2023. Trinseo is a materials solutions provider that manufactures and sells plastics and latex binders in the United States, Europe, the Asia-Pacific, and internationally.

What is this Case About: Trinseo PLC (TSE) Failed to Disclose the Multitude of Problems at its Bristol, PA Plant

According to the complaint, defendants failed to disclose that: (1) the Company’s Bristol, Pennsylvania plant had a troubled safety record while under prior ownership and continued to be unsafe after the Company acquired it; (2) defendants did not sufficiently disclose specific risks related to conducting operations at that plant; and (3) operating a chemical plant with an unsafe history and presently unsafe operations exposed the Company to a heightened risk of a chemical spill or other adverse event.

On March 26, 2023, the Company published an announcement on its website that stated, in pertinent part: “Altuglas, a subsidiary of Trinseo, is working with local, state and federal agencies to clean up the release of a latex emulsion product from its manufacturing facility in Bristol, PA. The release, which occurred Friday evening, March 24, appears to be the result of an equipment failure." The next day, The Philadelphia Inquirer released an article entitled “Bristol plant that spilled chemicals into Philly’s water supply had other mishaps over the last decade,” highlighting the decade-long problems at the plant. On this news, Trinseo’s stock fell $1.09 per share on March 27, 2023, or 5.2%, damaging investors.

What Now: Similarly situated shareholders may be eligible to participate in the class action against Trinseo. Shareholders who want to act as lead plaintiff for the class must file their papers by June 20, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas, Jr.
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders.

To be notified if a class action against Trinseo PLC settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:TSE

Release Summary
Trinseo PLC (TSE) Failed to Disclose the Multitude of Problems at its Bristol, PA Plant
Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Investor Alert: Robbins LLP Informs Investors of the Corcept Therapeutics Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Corcept Therapeutics Incorporation (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025. Corcept is a pharmaceutical company focused on the development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. For more information, submi...

ARDT Class Action Reminder: Stockholders Who Lost Money Investing in Ardent Health, Inc. Should Contact Robbins LLP for Information About Recovering Their Losses

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Ardent Health, Inc. (NYSE: ARDT) securities between July 18, 2025 and November 12, 2025. Ardent Health and its affiliates operate acute care hospitals and other healthcare facilities. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What are the allegations? Robbins LLP is Investigating...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the NuScale Power Corporation Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired NuScale Power Corporation (NYSE: SMR) Class A shares between May 13, 2025 and November 6, 2025. NuScale is a nuclear technology company focused on scalable, modular reactors. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that...
Back to Newsroom